Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: A new lanreotide autogel/depot (LAN) syringe was developed based on feedback from a human factors study to improve user experience.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Truong Thanh X, Adelman D, Feuilly M, Houchard A, Cella D,
Keywords: Somatuline lanreotide, syringe, neuroendocrine tumors, medical treatment,
Introduction: The long acting formulation of lanreotide autogel(LAN) can facilitate self-injection (SI) by patients or caregivers at home, avoiding visits to health centers. Training by nurses is required to ensure successful SI. Patient satisfaction(PS) is an important outcome of SI and home care programs.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Hernando J
Authors: Hernando J, Teulé A, Simó-Servat A, Serrano R, Venegas E,
Keywords: Lanreotide, Satisfaction, Home training,
Introduction: A new syringe (NS) for the delivery of lanreotide autogel was approved in Oct 2018 in France. The NS includes updated features (larger flanges, more robust plunger) intended to ease the injection.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Walter T, Eskenazi M, Rama N, Gueguen D, Mir O,
Keywords: neuroendocrine tumors, lanreotide, nursing, patient-reported outcomes,
Introduction: Somatostatin analogues (SSAs) are considered the gold standard for systemic therapy of advanced neuroendocrine tumors (NETs). Octreotide is one of the SSAs most widely used in long-term therapies of NETs. There is increasing evidence that clinical benefits could be obtained with higher SSAs circulating levels but remain unreachable with current products without impacting significantly the quality of life of the patients. APOC is a new injectable controlled release technology containing Octreotide invented and developed by Ascil-Biopharm and designed to cover specifically these clinical unmet needs. It is presented as ready-to-use and can easily be manufactured at selected doses and durations in prefilled syringe.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Antonijoan Arbós R, Lachamp L, Cabello F, Molina P, Coimbra J,
Keywords: Apoc, somatostatin, analogues, controlled release, octreotide, octreotide acetate, phase 1, studies, clinical trial, study, neuroendocrine, tumor, slow, release, formulation, therapeutics, injection, drug effect, clinical, trial, im, sc,